Mechanism
GH axis and visceral adiposity
The growth-hormone axis influences fat distribution, especially visceral fat. Tesamorelin is licensed in the US (Egrifta) for HIV-associated lipodystrophy and is the main human-licensed molecule acting via this pathway. CJC-1295, ipamorelin and similar growth-hormone-secretagogue research compounds are not licensed for human therapeutic use in the UK.
Plain-English explanation
The growth-hormone axis influences fat distribution, especially visceral fat. Tesamorelin is licensed in the US (Egrifta) for HIV-associated lipodystrophy and is the main human-licensed molecule acting via this pathway. CJC-1295, ipamorelin and similar growth-hormone-secretagogue research compounds are not licensed for human therapeutic use in the UK.
Research-level explanation
Tesamorelin has FDA approval for HIV-associated lipodystrophy; broader metabolic indications remain investigational. Research-only growth-hormone secretagogues (CJC-1295, ipamorelin) have not progressed to UK licensed indications.
Common misconceptions
| Common claim | More accurate framing |
|---|---|
| Growth-hormone-axis peptides are interchangeable with GLP-1 receptor agonists for obesity. | Mechanism, evidence base, regulatory status and safety profile differ substantially. Tesamorelin's licensed indication is HIV-associated lipodystrophy, not general obesity. |
Safety relevance
GH/IGF-1 axis activation has implications for glycaemic control and other organ systems; safety monitoring depends on the specific molecule and indication.
- Research-only compounds in the GH-secretagogue class do not have human-use evidence comparable to incretin medicines.
Related peptide profiles
Related trials
No published trials yet linked to this page. Source verification required.
Related conditions
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — Scientific guidelines
EMA scientific guidelines covering pharmacodynamic mechanisms
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of mechanism profiles on this site